New Approaches in the Management of Dementia-Related Psychosis (CME/CE Webcast)
Activity Description and Purpose
The prevalence of Alzheimer’s disease and related dementias is approximately 6 million, and is expected to increase to nearly 14 million by 2050. Along with a decline in cognition, driven by neurodegeneration, several behavioral and psychological symptoms of dementia are seen as the disease progresses. Hallucinations and delusions are among the more disruptive and burdensome symptoms for both caregivers and patients. Dementia-related psychosis (DRP) is usually treated with off-label antipsychotics, with variable efficacy for DRP and concerning safety profiles. Current best practices include a stepwise approach, wherein secondary causes are ruled out, nonpharmacologic approaches are attempted first, and pharmacologic treatment is initiated only if symptoms are severe, dangerous, and distressing. Although the data supporting use of antipsychotics in DRP are scarce, there is some existing evidence that risperidone, olanzapine, and aripiprazole might be efficacious. A growing body of clinical trial data on pimavanserin for DRP suggests that it might be efficacious, with an acceptable safety profile. In this webcast, experts will discuss current best practices in the identification and management of symptoms of psychosis in dementias, with challenging case discussions and a question-and-answer session. The desired results of this activity are for clinicians to recognize psychosis as part of the neurodegenerative process in dementia and treat symptoms effectively while maintaining the safety and quality of life of patients.
This educational activity is intended for psychiatrists and primary care providers caring for patients with DRP, including those practicing in the long-term care setting.
After completing this activity, participants will be better able to:
- Review clinical trial data for emerging treatments for DRP
- Develop evidence-based long-term treatment plans for patients with DRP
- Employ a collaborative care model for patients with DRP
Marc E. Agronin, MD (Chair)
Senior Vice President for Behavioral Health
Miami Jewish Health
Affiliate Associate Professor of Psychiatry and Neurology
University of Miami Miller School of Medicine
Gary W. Small, MD
Parlow-Solomon Professor on Aging
Professor of Psychiatry and Biobehavioral Sciences
David Geffen School of Medicine
Director, UCLA Longevity Center
Director, Geriatric Psychiatry Division
Semel Institute for Neuroscience and Human Behavior
Stewart and Lynda Resnick Neuropsychiatric Hospital
University of California, Los Angeles
Los Angeles, California
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.
Marc E. Agronin, MD, has no relevant commercial relationships to disclose.
Gary W. Small, MD, receives intellectual property rights from/is a patent holder of Ceremark Pharma; is on the speakers bureau for ACADIA Pharmaceuticals Inc; receives fees for non-CME/CE services from ACADIA Pharmaceuticals Inc, Avanir Pharmaceuticals, Inc, F. Hoffmann-La Roche, Genentech, Inc, Handok, Herbalife International of America, Inc, Reckitt Benckiser Group plc, and Theravalues; and has ownership interest in Ceremark Pharma.
Peer Reviewer Disclosure
Rita Khoury, MD, has no relevant commercial relationships to disclose.
Planners and Managers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Interprofessional Joint Accreditation Statement
In support of improving patient care, Amedco is jointly accredited by the ACCME, the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from ACADIA Pharmaceuticals Inc.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at email@example.com.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or ACADIA Pharmaceuticals Inc.
This CME activity is copyrighted to MedEdicus LLC ©2020. All rights reserved. 228
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation